+63 % change
Extra-EU imports of CN 30021500 were up 63% in 2025 compared with 2020 (€16.47 billion), calculated from Eurostat values.
Eurostat68.71 EUR billion
EU exports of CN 30021500 to countries outside the EU were worth €68.71 billion in 2025.
Eurostat54.86 EUR billion
Trade between EU member states in CN 30021500 (intra-EU arrivals) came to €54.86 billion in 2025.
EurostatSource: Eurostat
Why this market is moving now
- Extra-EU import value moved +63% from 2020 to 2025, a direct read on EU demand for sourced supply.
- Supply is concentrated: one country provided a large share of extra-EU imports in 2025.
- US employment in the core industry shifted +23% since 2020.
What this market covers
Follow on copies of approved antibody drugs for cancer and autoimmune disease, proven to match the original. Hospitals and health systems buy them at lower cost.
Typical segments
- Oncology antibodies
- Rheumatology antibodies
- Dermatology antibodies
- Eye disease antibodies
Who buys
- Hospitals
- Cancer centres
- Health insurers
Largest non-EU suppliers to the EU
| Country | Import value |
|---|---|
| Switzerland | 14,953.2 EUR million |
| United States from 1995 -> 2000) | 6,934.4 EUR million |
| Korea, Republic of | 1,996.4 EUR million |
| United Kingdom | 1,055.2 EUR million |
| Singapore | 895.1 EUR million |
| Japan | 232.4 EUR million |
Key figures
Each figure links to the page it came from.
| Figure | Value | Year | Source |
|---|---|---|---|
| The EU imported €26.91 billion of products under CN code 30021500 (Immunological products, put up in measured doses or in forms or packings for retail sale) from outside the EU in 2025. | 26.91 EUR billion | 2025 | Eurostat |
| Extra-EU imports of CN 30021500 were up 63% in 2025 compared with 2020 (€16.47 billion), calculated from Eurostat values. | +63 % change | 2025 | Eurostat |
| EU exports of CN 30021500 to countries outside the EU were worth €68.71 billion in 2025. | 68.71 EUR billion | 2025 | Eurostat |
| Trade between EU member states in CN 30021500 (intra-EU arrivals) came to €54.86 billion in 2025. | 54.86 EUR billion | 2025 | Eurostat |
| Switzerland was the largest non-EU supplier of CN 30021500 to the EU in 2025, with €14.95 billion, or 56% of extra-EU imports. | 14.95 EUR billion | 2025 | Eurostat |
| EU exports of CN 30021500 to the United States were €36.84 billion in 2025. | 36.84 EUR billion | 2025 | Eurostat |
| The average value of extra-EU imports of CN 30021500 was €5,399.06 per kilogram in 2025, calculated from Eurostat value and weight. | 5,399.06 EUR per kg | 2025 | Eurostat |
| Germany was the largest EU exporter of CN 30021500 to non-EU countries in 2025, at €23.00 billion. | 23.00 EUR billion | 2025 | Eurostat |
| The EU had 3,116 enterprises in NACE class C2120 (Manufacture of pharmaceutical preparations) in 2023. | 3,116 enterprises | 2023 | Eurostat |
| EU enterprises in NACE class C2120 had net turnover of €428.65 billion in 2023. | 428.65 EUR billion | 2023 | Eurostat |
| NACE class C2120 employed 600,730 people across the EU in 2023. | 600,730 persons employed | 2023 | Eurostat |
| The US had 830 private establishments in NAICS 325414 (Biological product (except diagnostic) manufacturing) in 2025. | 830 establishments | 2025 | U.S. Bureau of Labor Statistics |
| NAICS 325414 employed an average of 46,853 people in US private industry in 2025. | 46,853 jobs | 2025 | U.S. Bureau of Labor Statistics |
| US employment in NAICS 325414 changed by +23% between 2020 (38,064 jobs) and 2025, calculated from BLS figures. | +23 % change | 2025 | U.S. Bureau of Labor Statistics |
| Average annual pay in US NAICS 325414 was $124,162 in 2025. | 124,162 USD per year | 2025 | U.S. Bureau of Labor Statistics |
What the full report covers
- 1
Executive summary
The answer on two pages: size, growth and what drives it.
- 2
Market size and outlook
History, the current year and a five-year view with base, low and high cases.
- 3
Segments and regions
Splits by product, buyer and geography across the US, Europe and MEA.
- 4
Company profiles
The main players, how they compete and where they are investing.
- 5
Data and method
Every figure in Excel, with the sources and assumptions behind it.
- 01Executive summary
The answer in one page: size, direction and what moves it - 02Market definition and scope
What is in and out of the European Union market - 03Market size, 2021 to 2025
Historical series and growth rates - 04Outlook to 2031
Base, low and high scenarios with stated assumptions - 05Rules, policy and deadlines
Regulation and programmes that change demand - 06Drivers and barriers
What accelerates or slows adoption, by customer segment - 07Prices, costs and margins
Unit economics where public data allows - 08Competitive landscape
8 to 12 company profiles with recent moves - 09Opportunities and risks
For new entrants, suppliers and investors - 10Method and sources
Every assumption and source, listed
Included with the full report
- PDF report, 40 to 60 pages
- Excel data pack
- Ready-to-use charts
- Method note and assumptions
- Written to order in 5 working days
Frequently asked questions
How big is the EU biosimilar monoclonal antibodies market?
There is no single official market total. Eurostat trade data shows the EU imported €26.91 billion of goods under CN 30021500 from outside the EU in 2025 and exported €68.71 billion.
Where does the EU import biosimilar monoclonal antibodies from?
Switzerland was the largest non-EU supplier in 2025. The next largest were United States from 1995 -> 2000), Korea, Republic of, United Kingdom.
What is the average import price of biosimilar monoclonal antibodies in the EU?
Dividing Eurostat import value by weight gives about €5,399.06 per kilogram for CN 30021500 in 2025.
Which EU countries export the most biosimilar monoclonal antibodies?
Germany led EU exports to non-EU countries in 2025, followed by Ireland, Netherlands.
How many US companies are in the biosimilar monoclonal antibodies industry?
BLS counts 830 private establishments in NAICS 325414 (Biological product (except diagnostic) manufacturing), the closest official industry.
How many EU companies are in the biosimilar monoclonal antibodies industry?
Eurostat counts 3,116 enterprises in NACE class C2120 (Manufacture of pharmaceutical preparations).
Sources and method
The figures on this page come from the public sources listed below. Read how we work.
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30021500, partner EXT_EU27_2020, flow import, 2025, VALUE_IN_EUROS 26913259385
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30021500, flow import, 2020 VALUE_IN_EUROS 16469088406; 2025 VALUE_IN_EUROS 26913259385
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30021500, partner EXT_EU27_2020, flow export, 2025, VALUE_IN_EUROS 68707423731
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30021500, partner INT_EU27_2020, flow import, 2025, VALUE_IN_EUROS 54862600545
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30021500, partner CH, flow import, 2025, VALUE_IN_EUROS 14953191250
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30021500, partner US, flow export, 2025, VALUE_IN_EUROS 36837867565
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter EU27_2020, product 30021500, flow import, 2025, VALUE_IN_EUROS 26913259385, QUANTITY_IN_100KG 49848
- Eurostat: EU trade since 1988 by HS2-4-6 and CN8 (DS-045409) (2026-11-04)
DS-045409, reporter DE, product 30021500, partner EXT_EU27_2020, flow export, 2025, VALUE_IN_EUROS 22998012322
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs ENT_NR, 2023, 3116
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs NETTUR_MEUR, 2023, 428651
- Eurostat: Enterprises by detailed NACE Rev. 2 activity and special aggregates (sbs_ovw_act) (2026-11-04)
sbs_ovw_act, geo EU27_2020, nace_r2 C2120, indic_sbs EMP_NR, 2023, 600730
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325414, 2025 (2026-11-04)
QCEW 2025 annual, US000, private, NAICS 325414, annual_avg_estabs 830
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325414, 2025 (2026-11-04)
QCEW 2025 annual, US000, private, NAICS 325414, annual_avg_emplvl 46853
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325414, 2025 (2026-11-04)
QCEW 2020 annual_avg_emplvl 38064; 2025 annual_avg_emplvl 46853
- U.S. Bureau of Labor Statistics: QCEW annual averages, NAICS 325414, 2025 (2026-11-04)
QCEW 2025 annual, US000, private, NAICS 325414, avg_annual_pay 124162
Free sample
Get a free sample of this report
We send the table of contents, two sample chapters and the method note, usually within one working day. You owe us nothing for asking.
- Full table of contents
- Two sample chapters
- Method note and data outline